SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sarah L Mason, Roger A Barker, Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature, Expert Opinion on Pharmacotherapy, 2016, 17, 1, 41

    CrossRef

  2. 2
    Laetitia C Schwab, Shaady N Garas, Janelle Drouin-Ouellet, Sarah L Mason, Simon R Stott, Roger A Barker, Dopamine and Huntington’s disease, Expert Review of Neurotherapeutics, 2015, 15, 4, 445

    CrossRef

  3. 3
    Annie Killoran, Kevin M. Biglan, Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches?, Movement Disorders, 2014, 29, 11
  4. 4
    W. Wang, S. Yang, X. Zhang, J. Li, Drug repositioning by integrating target information through a heterogeneous network model, Bioinformatics, 2014, 30, 20, 2923

    CrossRef

  5. 5
    Calum D. Moulton, C.W.P. Hopkins, W. Richard Bevan-Jones, Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease, Movement Disorders, 2014, 29, 12
  6. 6
    Samuel Frank, Treatment of Huntington’s Disease, Neurotherapeutics, 2014, 11, 1, 153

    CrossRef

  7. 7
    Aleksandar Videnovic, Treatment of Huntington Disease, Current Treatment Options in Neurology, 2013, 15, 4, 424

    CrossRef

  8. 8
    Charles S. Venuto, Andrew McGarry, Qing Ma, Karl Kieburtz, Pharmacologic approaches to the treatment of Huntington's disease, Movement Disorders, 2012, 27, 1
  9. 9
    Raphael M. Bonelli, M. Flint Beal, Neurobiology of Psychiatric Disorders, 2012,

    CrossRef

  10. 10
    Okeanis Vaou, Samuel Frank, Managing chorea in Huntington’s disease, Neurodegenerative Disease Management, 2011, 1, 4, 295

    CrossRef

  11. 11
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  12. 12
    Samuel Frank, Joseph Jankovic, Advances in the Pharmacological Management of Huntingtonʼs Disease, Drugs, 2010, 70, 5, 561

    CrossRef

  13. 13
    &NA;, Although the symptoms of Huntingtonʼs disease can be treated, the course of the disease cannot currently be altered, Drugs & Therapy Perspectives, 2010, 26, 10, 11

    CrossRef

  14. 14
    Stefan Klöppel, Cynthia M. Stonnington, Predrag Petrovic, Dean Mobbs, Oliver Tüscher, David Craufurd, Sarah J. Tabrizi, Richard S.J. Frackowiak, Irritability in pre-clinical Huntington's disease, Neuropsychologia, 2010, 48, 2, 549

    CrossRef

  15. 15
    Erik van Duijn, Treatment of Irritability in Huntington’s Disease, Current Treatment Options in Neurology, 2010, 12, 5, 424

    CrossRef

  16. 16
    Sarah L Mason, Roger A Barker, Emerging drug therapies in Huntington's disease, Expert Opinion on Emerging Drugs, 2009, 14, 2, 273

    CrossRef

  17. 17
    The Maudsley Prescribing Guidelines, Tenth Edition, 2009,

    CrossRef

  18. 18
    Octavian R. Adam, Joseph Jankovic, Symptomatic treatment of Huntington disease, Neurotherapeutics, 2008, 5, 2, 181

    CrossRef

  19. 19
    Wendy Phillips, Kathleen M. Shannon, Roger A. Barker, The current clinical management of Huntington's disease, Movement Disorders, 2008, 23, 11
  20. 20
    Laura A. Wagner, Liliana Menalled, Alexander D. Goumeniouk, Daniela Brunner, Blair R. Leavitt, Animal and Translational Models for CNS Drug Discovery, 2008,

    CrossRef

  21. 21
    Alexandra Durr, Dementias, 2008,

    CrossRef

  22. 22
    Raphael M Bonelli, Peter Hofmann, A systematic review of the treatment studies in Huntington’s disease since 1990, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 141

    CrossRef

  23. 23
    Tomohide Roppongi, Takashi Togo, Shinichi Nakamura, Takeshi Asami, Asuka Yoshimi, Kazumasa Shiozaki, Daiji Kato, Chiaki Kawanishi, Yoshio Hirayasu, Perospirone in treatment of Huntington's disease: A first case report, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1, 308

    CrossRef

  24. 24
    Nora Selengut Brooke, Michelle Wiersgalla, Carl Salzman, Atypical Uses of Atypical Antipsychotics, Harvard Review of Psychiatry, 2005, 13, 6, 317

    CrossRef

  25. 25
    Zheng-hong QIN, Jin WANG, Zhen-lun GU, Development of novel therapies for Huntington's disease: hope and challenge, Acta Pharmacologica Sinica, 2005, 26, 2
  26. 26
    Erika Driver-Dunckley, Virgilio Gerald H Evidente, Hemichorea-Hemiballismus May Respond to Topiramate, Clinical Neuropharmacology, 2005, 28, 3, 142

    CrossRef

  27. 27
    Anthony J Hannan, Novel therapeutic targets for Huntington’s disease, Expert Opinion on Therapeutic Targets, 2005, 9, 4, 639

    CrossRef

  28. 28
    JAYARAMAN RAO, Animal Models of Movement Disorders, 2005,

    CrossRef

  29. 29
    Raphael M Bonelli, Peter Hofmann, A review of the treatment options for Huntington’s disease, Expert Opinion on Pharmacotherapy, 2004, 5, 4, 767

    CrossRef

  30. 30
    A. Reiner, Can lesions of GPe correct HD deficits?, Experimental Neurology, 2004, 186, 1, 1

    CrossRef

  31. 31
    Raphael M. Bonelli, Gregor K. Wenning, Hans P. Kapfhammer, Huntington??s disease: present treatments and future therapeutic modalities, International Clinical Psychopharmacology, 2004, 19, 2, 51

    CrossRef

  32. 32
    Dag Aarsland, Clive Ballard, Psychiatric issues in non-Alzheimer dementias, Clinical Neuroscience Research, 2004, 3, 6, 397

    CrossRef

  33. 33
    Katie Kompoliti, Cynthia L. Comella, Non-Parkinsonian Movement Disorders,
  34. 34
    Tiago Mestre, Joaquim Ferreira, Miguel M Coelho, Mário Rosa, Cristina Sampaio, Therapeutic interventions for symptomatic treatment in Huntington's disease, The Cochrane Library,